Moderna's mRNA-1273 Meets its Primary Endpoint in P-II/III TeenCOVE Study to Prevent COVID 19 in Adolescents
Shots:
- The P-II/III TeenCOVE study involves assessing mRNA-1273 (two 100 µg doses) vs PBO in 3700+ participants in a ratio (2:1) aged 12 to <18yrs. in the US
- The study met its 1EPs i.e non-inferior immunogenicity and demonstrated 93% efficacy in seronegative participants after 14 days following the first dose- was generally well tolerated with a safety and tolerability profile generally consistent with the P-III COVE study in adults
- Additionally- no cases of COVID-19 were seen in participants who had received both doses- consistent with a vaccine efficacy of 100%. The data will be submitted to regulators globally in early Jun’2021
Ref: Moderna | Image: Moderna
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com